Sulfoquinovosyl Acyl Panediol (SQAP) as a Radiation Sensitizer for Dogs with Tumors : A Pilot Study

機関リポジトリ

この論文をさがす

抄録

Sulfoquinovosylacylpanediol (SQAP) was discovered to be a radiation sensitizer in 1997. However, the safety of SQAP and radiotherapy to treat naturally occurring tumors in dogs remains unknown. The purpose of this study was to evaluate the safety of SQAP and hypofractionated radiotherapy in healthy beagle dogs, and dogs with tumors. Healthy beagle dogs were administered SQAP at doses of 0, 1, 2, 4, and 8 mg/kg for 5 consecutive days on the first week, while radiotherapy was performed once weekly for 4 weeks. Five dogs with soft tissue sarcoma, thyroid carcinoma, undifferentiated carcinoma, hemangiosarcoma, and liposarcoma were also enrolled in this prospective study. SQAP at 4 mg/kg was administered to the dogs with tumors. The adverse events of SQAP included angialgia in most cases. The adverse events of SQAP and radiotherapy were mild. The systemic administration of SQAP and concomitant radiotherapy appears to be safe for short-term use.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ